SIAH2 and prostate carcinoma: These compounds inhibit SIAH2 at the micromolar level of IC50 based on the cell viability assay using several melanoma and prostate cancer cell lines, with adapalene being a stronger inhibitor (Feng et al., 2019; Table 2).